TP53 and hepatocellular carcinoma: To date, numerous dysregulated and somatic mutations of genes and signaling pathways have been identified that play critical roles in HCC initiation and progression (Kan et al., 2013), including TP53 (Kan et al., 2013), UBE3C (Jiang et al., 2014), EGFR (Jang et al., 2017), SHP-1 (Wen et al., 2018) and JAK/STAT (Kan et al., 2013).